265 related articles for article (PubMed ID: 20047143)
1. hERG: protein trafficking and potential for therapy and drug side effects.
Staudacher I; Schweizer PA; Katus HA; Thomas D
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
[TBL] [Abstract][Full Text] [Related]
2. [Progress in research on defective protein trafficking and functional restoration in HERG-associated long QT syndrome].
Fang P; Lian J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Feb; 33(1):101-4. PubMed ID: 26829745
[TBL] [Abstract][Full Text] [Related]
3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
4. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
5. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.
Raschi E; Ceccarini L; De Ponti F; Recanatini M
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1005-21. PubMed ID: 19572824
[TBL] [Abstract][Full Text] [Related]
6. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
7. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Nogawa H; Kawai T
Eur J Pharmacol; 2014 Oct; 741():336-9. PubMed ID: 24998878
[TBL] [Abstract][Full Text] [Related]
8. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
9. hERG channel trafficking: novel targets in drug-induced long QT syndrome.
Dennis A; Wang L; Wan X; Ficker E
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1060-3. PubMed ID: 17956279
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of drug induced QT interval prolongation.
Ponte ML; Keller GA; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):44-53. PubMed ID: 20210718
[TBL] [Abstract][Full Text] [Related]
11. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
12. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Han S; Zhang Y; Chen Q; Duan Y; Zheng T; Hu X; Zhang Z; Zhang L
Eur J Pharmacol; 2011 Jan; 650(1):138-44. PubMed ID: 20951697
[TBL] [Abstract][Full Text] [Related]
14. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
15. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced hERG block and long QT syndrome.
Witchel HJ
Cardiovasc Ther; 2011 Aug; 29(4):251-9. PubMed ID: 20406244
[TBL] [Abstract][Full Text] [Related]
17. The effects of a novel anti-arrhythmic drug, acehytisine hydrochloride, on the human ether-a-go-go related gene K channel and its trafficking.
Huang X; Yang Y; Zhu J; Dai Y; Pu J
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):145-54. PubMed ID: 19143746
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
19. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Lu HR; Hermans AN; Gallacher DJ
Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
[TBL] [Abstract][Full Text] [Related]
20. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
Qu Y; Fang M; Gao B; Chui RW; Vargas HM
J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
